Anna H Mooney, Sarah L Draper, Olivia K Burn, Regan J Anderson, Benjamin J Compton, Chingwen Tang, Kathryn J Farrand, Pietro Di Lucia, Micol Ravà, Valeria Fumagalli, Leonardo Giustini, Elisa Bono, Dale I Godfrey, William R Heath, Weiming Yuan, Francis V Chisari, Luca G Guidotti, Matteo Iannacone, John Sidney, Alessandro Sette, Shivali A Gulab, Gavin F Painter, Ian F Hermans
BACKGROUND & AIMS: Liver diseases resulting from chronic HBV infection are a significant cause of morbidity and mortality. Vaccines that elicit T-cell responses capable of controlling the virus represent a treatment strategy with potential for long-term effects. Here, we evaluated vaccines that induce the activity of type I natural killer T (NKT) cells to limit viral replication and license stimulation of conventional antiviral T-cells. METHODS: Vaccines were prepared by conjugating peptide epitopes to an NKT-cell agonist to promote co-delivery to antigen-presenting cells, encouraging NKT-cell licensing and stimulation of T cells...
May 2024: JHEP reports: innovation in hepatology